Loxo Oncology Inc (NASDAQ:LOXO) CEO Joshua H. Bilenker sold 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 14th. The shares were sold at an average price of $131.54, for a total value of $1,973,100.00. Following the completion of the sale, the chief executive officer now directly owns 190,207 shares in the company, valued at approximately $25,019,828.78. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of Loxo Oncology Inc (NASDAQ:LOXO) opened at $125.83 on Friday. Loxo Oncology Inc has a 52-week low of $40.52 and a 52-week high of $135.74. The company has a market capitalization of $3,706.52, a P/E ratio of -24.01 and a beta of 2.37.
Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($0.69) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.22) by $0.53. The firm had revenue of $21.30 million during the quarter. equities analysts expect that Loxo Oncology Inc will post 3.81 earnings per share for the current year.
A number of research firms have issued reports on LOXO. Zacks Investment Research raised Loxo Oncology from a “hold” rating to a “buy” rating and set a $148.00 target price on the stock in a report on Friday, March 9th. Citigroup reiterated a “buy” rating and issued a $151.00 price objective (up previously from $108.00) on shares of Loxo Oncology in a research report on Monday, March 5th. Stifel Nicolaus reiterated a “buy” rating and issued a $135.00 price objective on shares of Loxo Oncology in a research report on Friday, March 2nd. Cann reiterated a “buy” rating and issued a $122.00 price objective on shares of Loxo Oncology in a research report on Thursday, March 1st. Finally, BidaskClub upgraded Loxo Oncology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 24th. Eleven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $124.44.
Several institutional investors have recently bought and sold shares of LOXO. State Board of Administration of Florida Retirement System lifted its position in shares of Loxo Oncology by 16.7% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 9,760 shares of the biopharmaceutical company’s stock worth $899,000 after buying an additional 1,400 shares during the period. New York State Common Retirement Fund lifted its position in shares of Loxo Oncology by 2.9% during the 3rd quarter. New York State Common Retirement Fund now owns 25,097 shares of the biopharmaceutical company’s stock worth $2,312,000 after buying an additional 700 shares during the period. Rhumbline Advisers lifted its position in shares of Loxo Oncology by 11.5% during the 3rd quarter. Rhumbline Advisers now owns 25,234 shares of the biopharmaceutical company’s stock worth $2,325,000 after buying an additional 2,608 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Loxo Oncology by 3.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 121,558 shares of the biopharmaceutical company’s stock worth $11,198,000 after buying an additional 4,018 shares during the period. Finally, Cambridge Investment Research Advisors Inc. bought a new position in shares of Loxo Oncology during the 3rd quarter worth approximately $212,000.
TRADEMARK VIOLATION WARNING: “Loxo Oncology Inc (LOXO) CEO Sells $1,973,100.00 in Stock” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/03/18/loxo-oncology-inc-loxo-ceo-sells-1973100-00-in-stock.html.
About Loxo Oncology
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.